Boston Scientific has announced a significant step forward by agreeing to acquire Penumbra, Inc. This deal aims to enhance Boston Scientific’s cardiovascular lineup and tackle the growing issue of vascular diseases.
Both companies will merge in a cash and stock transaction valued at $374 per share for Penumbra, totaling around $14.5 billion. This acquisition will provide Boston Scientific a solid entry point into key areas like mechanical thrombectomy and neurovascular treatments.
Mike Mahoney, CEO of Boston Scientific, expressed excitement about this acquisition, highlighting Penumbra’s strong team and innovative technologies. He believes this combination will provide more patients access to advanced medical solutions while boosting the company’s revenue and growth potential.
Cardiovascular diseases, the leading cause of death worldwide, include conditions that hinder blood flow, often leading to serious complications like strokes and heart attacks. Penumbra has developed a diverse portfolio specifically to combat these issues. Their technology includes advanced products for mechanical thrombectomy, aimed at safely removing blood clots from critical areas in the body.
Penumbra reported impressive growth, with an anticipated revenue increase of about 21.4% during the fourth quarter of 2025 and a full-year projected revenue of around $1.4 billion. This reflects an annual growth rate of approximately 17.5%. The company is committed to ongoing research and development, solidifying its position at the forefront of medical technology.
The deal is designed to be beneficial for shareholders, allowing them to choose between cash or stock from Boston Scientific. The cash portion is expected to be financed through available cash and new debt.
The merger is projected to complete in 2026, subject to Penumbra’s shareholder approval and other closing conditions. As the healthcare landscape evolves, collaborations like these highlight the urgency to innovate in the face of rising health challenges, especially in cardiovascular sectors.
For further details, the Boston Scientific investor relations website will provide updates as the acquisition process unfolds.
Related Resources:
